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Who Is at Risk? At What Age? When and How Often
Should We Evaluate to Determine Risk?*Frank Marcus, MD,y Luisa Mestroni, MDzA rrhythmogenic right ventricular cardiomy-opathy (ARVC) is being recognized withincreasing frequency as physicians have
become more aware of this entity. Some estimate
that ARVC may be present in 1 in 5,000 people. The
disease is primarily caused by an autosomal domi-
nant genetic defect. Therefore, a person with ARVC
has a 50% chance of transmitting this disease to his
or her offspring, which can cause marked anxiety
because it is well known that ARVC can cause
arrhythmic death. However, it is also clear that there
is no close relation between an individual who has the
genetic abnormality and the clinical manifestations
of the disease. This is known as a lack of association
of genotype with the phenotypic expression of the
disease.
The obvious question that arises when a patient
is diagnosed with ARVC is whether the ﬁrst-degree
relatives should have genetic testing for the genes
responsible for ARVC. Of the 11 genes currently
described in ARVC, the majority of cases are caused
by mutations in 5 desmosomal genes. Desmosomes
are specialized intercellular junctions that provide
myocyte-to-myocyte adhesion. Also, the question
arises as to the age at which a clinical evaluation
should be conducted in relatives and how the* Editorials published in the Journal of the American College of Cardiology
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uation should be used.
It is now known that 30% to 50% of patients with
ARVC have mutations in at least 1 of the genes
responsible for the disease. The remainder of patients
with ARVC have undiscovered genetic abnormalities
or have the disease de novo. If a pathogenic mutation
is found in the affected individual (proband), genetic
testing is indicated in ﬁrst-degree relatives. However,
if the proband does not have a pathological ARVC
gene mutation, genetic testing in the related family
members is not indicated, because the identiﬁcation
of a rare variant will have unknown signiﬁcance.
Thus, the genetics of this disease are complex, and
consultation with a genetic counselor can be most
helpful.
Another important question is at what age family
members of a proband who has a pathological gene
and is suspected of having the disease should be
evaluated. Genetic testing can be performed at any
age; however, clinical evaluation should be guided by
the consistent observation that sudden cardiac death
(SCD) caused by ARVC is extremely rare at <10 years
of age. In a recently published study of the causes
of SCD in children (1), there was a single 10-year-old
child who had ARVC and SCD. No deaths occurred
below the age of 10 years. There were 7 others with
ARVC who died between the ages of 14 and 19 years.
This information was based on a study conducted in
Ontario, Canada, during a 5-year period from 2005 to
2009 that involved individuals 1 to 19 years of age
and included 116 cases of adjudicated SCD. Because
electrical abnormalities such as premature ventricu-
lar beats occur before structural abnormalities in the
right or left ventricle, it is of questionable value to
attempt to assess morphological abnormalities in
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303family members by magnetic resonance imaging
before 10 years of age. Knowledge of the relation of
the structural and electrical abnormalities of the dis-
ease and the rate of progression of these abnormal-
ities in ARVC would assist in determining at what
age and how frequently a practitioner should repeat
evaluation of electrical and structural abnormalities
of family members with ARVC who do not meet the
2010 modiﬁed Task Force Criteria (TFC) at baseline.SEE PAGE 293The study by te Riele et al. (2) in this issue of the
Journal addresses this question. They analyzed the
data of 37 relatives who had complete baseline eval-
uation and follow-up evaluation with a mean of 4.1 
2.3 years. These 37 family members had a risk of
developing ARVC. Of these, 28 (76%) were mutation
carriers but did not meet TFC. Over this duration of
time, electrical progression by electrocardiographic
Holter monitoring or signal-averaged electrocardiog-
raphy occurred in 27%, whereas structural progres-
sion was found in only 1 of the 37 patients. This
ﬁnding has clinical relevance, because it is well
documented that structural lesions of the right
ventricle by imaging are subject to considerable error
and must be interpreted with caution. Misinterpre-
tation of structural abnormalities by magnetic reso-
nance imaging has been noted to be common (3), and
a false interpretation of the right ventricle as enlarged
may cause anxiety and could lead to unwarranted
insertion of an implantable cardioverter-deﬁbrillator
(ICD).
In the report by te Riele et al. (2), 8 of the 43 family
members with deﬁnite criteria for ARVC at the ﬁrst
evaluation had an arrhythmic event during 3.2  2.4
years of follow-up; however, none of the subjects
who did not meet modiﬁed TFC at ﬁrst evaluation
developed sustained ventricular arrhythmias. These
data suggest that family members who do not meet
the 2010 TFC for the diagnosis of ARVC have anexcellent prognosis over a 4-year period and are un-
likely to have structural progression during this time.
An important contribution of the paper by te Riele
et al. (2) is that evaluation of family members who
do not meet the TFC should be focused on electrical
abnormalities and not on structural changes; how-
ever, those family members who meet the TFC should
be observed closely for electrical progression. It is
not clear how best to treat arrhythmic events in
these patients to prevent recurrent ventricular ar-
rhythmias or SCD—whether by antiarrhythmic drugs
or ICD insertion. ICDs are associated with signiﬁ-
cant device or lead malfunction. Another treatment
option that is being evaluated is the use of both
endocardial and epicardial ablation to eliminate
ventricular arrhythmias.
In this study (2), the investigators did not use the
criteria of Hamid et al. (4) to classify the disease
status in ﬁrst-degree family members, although the
data using the Hamid et al. criteria to classify family
members are shown in Online Tables 3 and 4. These
criteria take into account the higher probability of
having ARVC in relatives than in the general popu-
lation and provide higher sensitivity in detecting
the disease.
Despite this limitation and the need for further
investigation, the paper by te Riele et al. (2) provides
important insights for the clinical practitioner, indi-
cating that the evaluation of disease progression in
family members who do not meet the TFC for ARVC
should focus on evaluation of the electrical aspects of
ARVC with simple and available methods (electro-
cardiography, Holter monitoring) rather than with
costly and often unreliable information from cardiac
magnetic resonance imaging.
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